These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 15349563)

  • 1. Superficial bladder cancer therapy.
    Schenkman E; Lamm DL
    ScientificWorldJournal; 2004 Jun; 4 Suppl 1():387-99. PubMed ID: 15349563
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy of bladder cancer.
    Nseyo UO; Lamm DL
    Semin Surg Oncol; 1997; 13(5):342-9. PubMed ID: 9259090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapy of superficial bladder cancer.
    Nseyo UO; Lamm DL
    Semin Oncol; 1996 Oct; 23(5):598-604. PubMed ID: 8893870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravesical therapy for superficial bladder cancer.
    Baselli EC; Greenberg RE
    Oncology (Williston Park); 2000 May; 14(5):719-29; discussion 729-31, 734, 737. PubMed ID: 10853462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy for bladder cancer.
    Kamat AM; Lamm DL
    Curr Urol Rep; 2001 Feb; 2(1):62-9. PubMed ID: 12084297
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term follow-up of intravesical bacillus Calmette-Guérin treatment for superficial transitional-cell carcinoma of the bladder involving the prostatic urethra.
    Taylor JH; Davis J; Schellhammer P
    Clin Genitourin Cancer; 2007 Sep; 5(6):386-9. PubMed ID: 17956711
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Photodynamic therapy using porfimer sodium as an alternative to cystectomy in patients with refractory transitional cell carcinoma in situ of the bladder. Bladder Photofrin Study Group.
    Nseyo UO; Shumaker B; Klein EA; Sutherland K
    J Urol; 1998 Jul; 160(1):39-44. PubMed ID: 9628601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk factors for positive findings in patients with high-grade T1 bladder cancer treated with transurethral resection of bladder tumour (TUR) and bacille Calmette-Guérin therapy and the decision for a repeat TUR.
    Orsola A; Cecchini L; Raventós CX; Trilla E; Planas J; Landolfi S; de Torres I; Morote J
    BJU Int; 2010 Jan; 105(2):202-7. PubMed ID: 19558557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.
    Lamm DL; Blumenstein BA; Crissman JD; Montie JE; Gottesman JE; Lowe BA; Sarosdy MF; Bohl RD; Grossman HB; Beck TM; Leimert JT; Crawford ED
    J Urol; 2000 Apr; 163(4):1124-9. PubMed ID: 10737480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Photodynamic therapy (PDT) in the treatment of patients with resistant superficial bladder cancer: a long-term experience.
    Nseyo UO; DeHaven J; Dougherty TJ; Potter WR; Merrill DL; Lundahl SL; Lamm DL
    J Clin Laser Med Surg; 1998 Feb; 16(1):61-8. PubMed ID: 9728133
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of intravesical chemotherapy versus BCG immunotherapy on recurrence of superficial transitional cell carcinoma of the bladder: metaanalytic reevaluation.
    Huncharek M; Kupelnick B
    Am J Clin Oncol; 2003 Aug; 26(4):402-7. PubMed ID: 12902895
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Photodynamic therapy in the management of bladder cancer.
    Nseyo UO
    J Clin Laser Med Surg; 1996 Oct; 14(5):271-80. PubMed ID: 9612193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The influence of intravesical therapy on progression of superficial transitional cell carcinoma of the bladder: a metaanalytic comparison of chemotherapy versus bacilli Calmette-Guerin immunotherapy.
    Huncharek M; Kupelnick B
    Am J Clin Oncol; 2004 Oct; 27(5):522-8. PubMed ID: 15596924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recurrence, progression and success in stage Ta grade 3 bladder tumors treated with low dose bacillus Calmette-Guerin instillations.
    Lebret T; Bohin D; Kassardjian Z; Herve JM; Molinie V; Barre P; Lugagne PM; Botto H
    J Urol; 2000 Jan; 163(1):63-7. PubMed ID: 10604315
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bladder contracture: review for intravesical bacillus Calmette-Guerin complication.
    Hameed A; Sezian N; Thwaini A
    Can J Urol; 2007 Dec; 14(6):3745-9. PubMed ID: 18163926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravesical therapy for superficial bladder cancer.
    Malkowicz SB
    Semin Urol Oncol; 2000 Nov; 18(4):280-8. PubMed ID: 11101091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guérin-Tice versus bacillus Calmette-Guérin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group.
    Witjes WP; Witjes JA; Oosterhof GO; Debruyne MJ
    Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):10-6. PubMed ID: 8727805
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conservative treatment of high grade superficial bladder tumours.
    Trinchieri A; Bonacina P; Butti A; Cappoli S; Esposito N; Invernizzi S; Librizzi A; Locatelli G
    Arch Ital Urol Androl; 2005 Dec; 77(4):215-8. PubMed ID: 16444936
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-risk superficial bladder cancer: intravesical therapy for T1 G3 transitional cell carcinoma of the urinary bladder.
    Pham HT; Soloway MS
    Semin Urol Oncol; 1997 Aug; 15(3):147-53. PubMed ID: 9394909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chlorin e6-polyvinylpyrrolidone mediated photodynamic therapy--A potential bladder sparing option for high risk non-muscle invasive bladder cancer.
    Lee LS; Thong PS; Olivo M; Chin WW; Ramaswamy B; Kho KW; Lim PL; Lau WK
    Photodiagnosis Photodyn Ther; 2010 Dec; 7(4):213-20. PubMed ID: 21112542
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.